Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CytoGam as Adjuvant Therapy for CMV in Solid Organ Transplant Recipients
NCT07009548Phase 4Enrolling by invitation
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of IgPro10 in cytomegalovirus infection (CMV). Started Jun 2025; status: enrolling by invitation.
02
Drugs
IgPro10
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07009548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009548.